Breakthrough Therapeutics, MolecularMD deal

Under a two-year deal, MolecularMD will monitor residual disease levels in patients in a Phase II trial of Breakthrough's Ablvax (VAX100) vaccine to treat Gleevec-resistant chronic myeloid leukemia (C...